2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101721
    Ko-3290 79848-61-6 98%
    Ko-3290 is an antagonist of β-adrenoceptor, with cardioselectivity and antilipolytic effects in animals. Ko-3290 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ko-3290
  • HY-101727
    Nexopamil racemate 116759-35-4 98%
    Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro.
    Nexopamil racemate
  • HY-101733
    Zabicipril hydrochloride 90130-77-1 98%
    Zabicipril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril hydrochloride can be used for the study of blood pressure and peripheral arterial insufficiency.
    Zabicipril hydrochloride
  • HY-101775
    9-Hydroxyellipticin 51131-85-2 98%
    9-hydroxyellipticine is an inhibitor of Topo II and RyR, exhibiting high affinity for DNA with a Pka value of 9.8 at pH 7.4. It has antitumor, antioxidant, and catecholamine-releasing activities, with IC50 values of 1.6 μM and 1.2 μM for Hela S-3 and 293T cells, respectively. It also demonstrates anticancer effects in L1210 leukemia mice.
    9-Hydroxyellipticin
  • HY-101804
    (E)-Alprenoxime 125720-84-5 98%
    (E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker.
    (E)-Alprenoxime
  • HY-101807
    Ro-15-2041 77448-87-4 98%
    Ro 15-2041 is a selective platelet phosphodiesterase inhibitor with antithrombotic properties.
    Ro-15-2041
  • HY-101809
    CNS-5161 hydrochloride 160756-38-7 98%
    CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS-5161 hydrochloride
  • HY-101811
    LAS-31180 137338-43-3 98%
    LAS-31180 is an inhibitor of phosphodiesterase 3, with positive inotropic and vasodilator properties.
    LAS-31180
  • HY-102092
    FR139317 142375-60-8 98%
    FR139317 (PD 147953) is a selective ETA receptor antagonist. FR139317 inhibits cerebral activation by intraventricular endothelin-1 in conscious rats. FR139317 also ameliorates cerebral vasospasm in dogs.
    FR139317
  • HY-10264D
    (1R,2R,4R)-Edoxaban 1255529-24-8 98%
    (1R,2R,4R)-Edoxaban is an oxalamide derivative. (1R,2R,4R)-Edoxaban is an activated coagulation factor X (Factor Xa) inhibitor. (1R,2R,4R)-Edoxaban can be used in the study of thrombosis.
    (1R,2R,4R)-Edoxaban
  • HY-10309R
    Sibrafiban (Standard) 172927-65-0 98%
    Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
    Sibrafiban (Standard)
  • HY-103212
    Azepexole dihydrochloride 36067-72-8 98%
    Azepexole (B-HT 933) dihydrochloride is a potent and selective alpha 2-adrenoceptor agonist with pKis of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively. Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions (IC50= 78.72 nM).
    Azepexole dihydrochloride
  • HY-103336
    Tocrifluor 1117 1186195-59-4 98%
    Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm).
    Tocrifluor 1117
  • HY-103458
    BMS 182874 hydrochloride 1215703-04-0 98%
    BMS 182874 hydrochloride is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 hydrochloride reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research.
    BMS 182874 hydrochloride
  • HY-10419A
    AH23848 hemicalcium salt 81496-19-7 98%
    AH23848 hemicalcium salt is a potent, specific and orally active thromboxane receptor blocker. AH23848 hemicalcium salt inhibits platelet deposition.
    AH23848 hemicalcium salt
  • HY-105010
    FK-739 free base 133052-30-9 98%
    FK-739 (free base) is an angiotensin II type 1 (AT1) receptor antagonist used in the study of hypertension.
    FK-739 free base
  • HY-10521R
    Darapladib (Standard) 356057-34-6
    Darapladib (Standard) is the analytical standard of Darapladib. This product is intended for research and analytical applications. Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer.
    Darapladib (Standard)
  • HY-105259
    SR 43845 114037-60-4 98%
    SR 43845 is a renin inhibitor. SR 43845 decreases blood pressure and inhibits plasma renin activity. SR 43845 can be used for hypertension research.
    SR 43845
  • HY-105351
    CGS25155 150126-87-7 98%
    CGS25155 is an orally active neutral endopeptidase 24.11 (NEP 24.11) inhibitor with an IC50 of 3 nM. CGS25155 can slow down the degradation of the cardiac hormone atrial natriuretic peptide (ANP) and exhibits antihypertensive activity in the DOCA-salt induced rat hypertension model. CGS25155 can be used in cardiovascular disease research.
    CGS25155
  • HY-105392
    LB30057 184770-78-3 98%
    LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC50 value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model.
    LB30057
Cat. No. Product Name / Synonyms Application Reactivity